Gabapentin Tablet, Film Coated
Product Images NDC 0904-7108

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 0904-7108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

E6746052 Be65 4002 B833 4b2a140b92ef 00

This is a description of a medication called Gabapentin in a Unit Dose package of 100 tablets. The pharmacist is instructed to dispense it with a medication guide, and it is only available with a prescription. The tablets contain 300mg of Gabapentin USP and the dosage instructions can be found on the product insert or prescribing information. The medication should be stored between 0°C and 25°C and kept out of reach of children. The package is not child-resistant and should be used up to completion.*

FDA Label Image

E6746052 Be65 4002 B833 4b2a140b92ef 01

This is a label of Gabapentin Tablets, USP by Major Pharmaceuticals which contains 100 tablets in a unit dose packaging. It has an NDC number of 0904-6823-61 and it can only be dispensed by a pharmacist with a medication guide. The label includes information on storage instructions and a website link to the manufacturer's website. No information is available on the dosage, indications or side-effects of the medication.*

FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

This appears to be a formula for calculating a value called "Lt" using a person's age and weight (in kilograms) multiplied by a factor of 140, and then diving the result by their creatinine level (in grams). The formula specifies that a creatinine value of 0.85 should be used for female patients. It is not clear what this value represents or how it is used in a medical context.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

The text is a caption for a figure showing weekly mean pain scores observed in a study. The study compared the effects of a placebo and Gabapentin (at a dosage of 300 mg/day) on pain. The figure shows the pain scores for each week along with markers for the mean pain score for each treatment group. The text includes some jumbled characters and does not provide any additional information.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

This appears to be a table or chart that is not readable, most likely it is not available.*

FDA Label Image

Chemical Structure (Gabapentin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.